glp-1 obesity drug supply news today weight loss drugs leave users low on key nutrients, study finds Medicare already covers GLP-1s for

Tresiba typically causes weight gain of 1 to 4 kg, which is the opposite of GLP-1 medications that produce significant weight loss

Consistent with these data, while exendin-4 but not GLP-1 (936) has infarct limiting potential in the isolated rat heart, exendin-4 and GLP-1 (936) both improve left ventricular performance during reperfusion [626]

1 As of 2025, roughly 10 million Americans 2 are on GLP-1s, for both treatment of type 2 diabetes and weight loss, and that number is expected to reach 25 million by 2030

Net prices of branded GLP-1s would have to come down further in order for them to be cost-saving within, say, a two-year time period

10.1056/NEJMoa1901118 42 IyerS